LETI is an independent, family-owned Spanish biopharmaceutical company that specializes in allergy, dermatology, and animal health products. It is known as LETI Pharma or Laboratorios LETI S.L. and has been in operation since 1919.

Company Profile

Founded:
1919.

Headquarters:
Barcelona, Spain, with research and manufacturing facilities near Madrid.

Focus Areas:

Human Health:
Immunology/Allergy (allergen immunotherapy and diagnostics) and Dermatology/Dermocosmetics (skincare and hygiene products).

Animal Health:
Solutions for veterinary immunology and dermatology, including a vaccine against canine Leishmaniasis (LetiFend).

Innovation:
LETI invests significantly in R&D (10-20% of revenue) and has a history of innovation, including being the first company to produce penicillin and an influenza vaccine in Spain.

Presence:
The company is a Spanish multinational with a solid international presence, including subsidiaries in Germany and Portugal, and partnerships in the US.

Product Lines (Dermatology Focus)

The EANs listed are linked to specific products within LETI’s dermo-pharmaceutical range, which are designed to improve quality of life for people with specific skin needs. Key product lines include:

LETI AT4:
A line of advanced emollient products for the care and treatment of atopic (eczema-prone) skin, suitable for the entire family.

LETIbalm:
Products focused on the repair and hydration of the nose and lips, especially in harsh conditions.

LETI SR (Sensitive Red Skin):
Products, such as mineral creams with SPF, designed to care for sensitive skin prone to redness (couperose/rosacea).